Talk of testosterone deficiency is hard to escape these days, with podcasters and politicians obsessing over how to avoid a “low T” lifestyle.
\n\nAs the hormone’s cultural salience deepens, demand is growing. In a timely move, telehealth giant Hims just launched a testosterone replacement therapy service for cisgender men.
\n\nThe direct-to-consumer juggernaut will offer two types of injectable treatments, as well as an oral pill option that can be sent to patients after they take an at-home capillary blood test. Peter Stahl, a urologist and a senior vice president of men’s health at Hims, wants to “cast as wide a net, and get as many people tested, as possible.”
\n\nHims, which started out selling erectile dysfunction medications, has expanded into women’s health and grown from a startup to a publicly traded company serving 2.9 million customers since it launched in 2017. Offering testosterone replacement therapy, or TRT, is both a new phase for the health platform and a doubling down on men’s health care. “When we first started, we didn't have the capabilities to take care of a complex condition like testosterone deficiency,” Stahl says. “We've finally grown up.”
\n\nThe company will compete with a wide array of online clinics…
Original source: https://www.wired.com/